PDGFRB and renal cell carcinoma: Sorafenib (NexavarTM), a multi-kinase inhibitor directed against a broad range of protein kinases (e.g. VEGFR, PDGFR, Raf) is the only medicament approved for the treatment of advanced hepatocellular cancer and advanced renal cell carcinoma to date and was used here as reference therapeutic treatment [48].